Monday, November 05, 2012 5:10:04 PM
Also:
1 Not yet recruiting Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Zoptarelin doxorubicin; Drug: paclitaxel; Drug: nab-paclitaxel; Drug: eribulin; Drug: pegylated liposomal doxorubicin; Drug: vinorelbine; Drug: gemcitabine; Drug: capecitabine
2 Recruiting Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Prostate Cancer; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Drug: doxorubicin-GnRH agonist conjugate AEZS-108
3 Completed
Has Results Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Condition: Benign Prostatic Hypertrophy
Intervention: Drug: Cetrorelix Pamoate
4 Recruiting A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
Condition: Urothelial Carcinoma
Interventions: Drug: AEZS-108; Drug: AEZS-108 at MTD
5 Completed Investigation of a New, Oral Growth Hormone Secretagogue, Macimorelin (AEZS-130) as a Growth Hormone Stimulation Test.
Condition: Diagnosis of Adult Growth Hormone Deficiency (AGDH)
Intervention: Other: macimorelin as a diagnostic
6 Completed Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors
Conditions: Ovarian Cancer; Endometrial Cancer
Intervention: Drug: AEZS-108
7 Completed
Has Results Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Condition: Benign Prostatic Hypertrophy
Interventions: Drug: Cetrorelix 78+78; Drug: Cetrorelix 78 + Placebo; Other: Placebo
8 Recruiting Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
Condition: Cancer Cachexia
Interventions: Drug: Macimorelin; Drug: Placebo
___________________________________________________
http://www.clinicaltrials.gov/ct2/results?term=aezs&Search=Search
AEZS
1 Not yet recruiting Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Zoptarelin doxorubicin; Drug: paclitaxel; Drug: nab-paclitaxel; Drug: eribulin; Drug: pegylated liposomal doxorubicin; Drug: vinorelbine; Drug: gemcitabine; Drug: capecitabine
2 Recruiting Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Prostate Cancer; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Other: questionnaire administration; Drug: doxorubicin-GnRH agonist conjugate AEZS-108
3 Completed
Has Results Cetrorelix Pamoate IM Regimens in Patients With Symptomatic Benign Prostatic Hyperplasia (BPH)
Condition: Benign Prostatic Hypertrophy
Intervention: Drug: Cetrorelix Pamoate
4 Recruiting A Phase I/II Trial of AEZS-108 in Urothelial Cancer Patients Who Failed Platinum-chemotherapy
Condition: Urothelial Carcinoma
Interventions: Drug: AEZS-108; Drug: AEZS-108 at MTD
5 Completed Investigation of a New, Oral Growth Hormone Secretagogue, Macimorelin (AEZS-130) as a Growth Hormone Stimulation Test.
Condition: Diagnosis of Adult Growth Hormone Deficiency (AGDH)
Intervention: Other: macimorelin as a diagnostic
6 Completed Antitumoral Activity and Safety of AEZS-108 in Women With LHRH Receptor Positive Gynecological Tumors
Conditions: Ovarian Cancer; Endometrial Cancer
Intervention: Drug: AEZS-108
7 Completed
Has Results Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)
Condition: Benign Prostatic Hypertrophy
Interventions: Drug: Cetrorelix 78+78; Drug: Cetrorelix 78 + Placebo; Other: Placebo
8 Recruiting Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Cachexia
Condition: Cancer Cachexia
Interventions: Drug: Macimorelin; Drug: Placebo
___________________________________________________
http://www.clinicaltrials.gov/ct2/results?term=aezs&Search=Search
AEZS
Recent CSCIF News
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 05/20/2026 08:46:58 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/20/2026 08:38:12 PM
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 05/12/2026 09:21:59 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/12/2026 09:07:13 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/12/2026 09:05:51 PM
- COSCIENS Biopharma Inc. Reports Q1 2026 Results • GlobeNewswire Inc. • 05/12/2026 09:05:00 PM
- Form SC 13E3/A - Going private transaction by certain issuers: [Amend] • Edgar (US Regulatory) • 05/08/2026 08:45:33 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/08/2026 08:45:07 PM
- Form SC 13E3 - Going private transaction by certain issuers • Edgar (US Regulatory) • 04/20/2026 12:01:09 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/20/2026 12:00:12 PM
- COSCIENS Biopharma Inc. Provides Update on its Plan to Suspend U.S. Public Company Reporting Obligations • GlobeNewswire Inc. • 04/20/2026 12:00:00 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/17/2026 09:55:15 PM
- COSCIENS Comments on Unusual Market Activity • GlobeNewswire Inc. • 04/07/2026 09:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/07/2026 09:07:44 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/25/2026 09:05:27 PM
- COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/25/2026 09:05:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/19/2026 04:15:19 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 03/13/2026 09:30:57 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 03/13/2026 09:30:39 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 03/13/2026 09:30:14 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 03/13/2026 09:29:54 PM
